[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368152-105":59,"doc-detail-368152-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","utilizing-patient-derived-xenografts-to-model-precision-oncology-for-biliary-tract-cancer","Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer","","Biliary tract cancers are rare, aggressive malignancies with diverse, clinically actionable molecular alterations, but clinically relevant models that capture this heterogeneity are limited. This study curated a collection of patient-derived xenograft (PDX) models spanning genomic alterations found in biliary tract tumors to support precision oncology modeling. PDXs were generated from surgical resections or metastatic biopsies, characterized by whole-exome sequencing and RNA sequencing, and treated with approved and investigational agents. Efficacy was evaluated using tumor volume change and event-free survival defined by tumor doubling. Results identified key actionable genomic alterations and transcriptomic fusions and antibody–drug conjugate target expression, enabling therapeutic matching with objective antitumor responses. The resulting catalog represents a large, comprehensively profiled resource to facilitate personalized treatments for these malignancies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/utilizing-patient-derived-xenografts-to-model-precision-oncology-for-biliary-tract-cancer/368152/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/utilizing-patient-derived-xenografts-to-model-precision-oncology-for-biliary-tract-cancer/368152.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why were patient-derived xenograft models needed for biliary tract cancers?","Question",{"text":112,"@type":113},"Clinically relevant biliary tract cancer models are scarce and often fail to reflect the tumors’ diverse molecular profiles. PDX models were curated to represent this genomic spectrum for precision oncology research.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the PDX models developed and molecularly characterized?",{"text":117,"@type":113},"PDXs were derived from biliary tract cancer samples from surgical resections or metastatic biopsies. Whole-exome sequencing and RNA sequencing were used to identify alterations present in the models.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of molecular alterations and targets were identified?",{"text":121,"@type":113},"Genomic sequencing revealed actionable alterations including FGFR2, IDH1, ERBB2, PIK3CA, PTEN, and KRAS. RNA sequencing showed fusions and expression of antibody–drug conjugate targets including TROP2, HER2, and Nectin4.",{"name":123,"@type":110,"acceptedAnswer":124},"How was treatment efficacy assessed and how were responses categorized?",{"text":125,"@type":113},"Efficacy was assessed by change in tumor volume from baseline, and event-free survival was defined as the time to tumor doubling. Responses at day 21 were categorized using tumor shrinkage and growth thresholds to distinguish objective responses from stable disease.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368152,1790864044,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer  \nTimothy P. DiPeri1, Kurt W. Evans2, Stephen Scott2, Xiaofeng Zheng3, Kaushik Varadarajan1, Lawrence N. Kwong4, Michael Kahle5,6, Hop S. Tran Cao1, Ching-Wei Tzeng1, Thuy Vu5,6, Sunhee Kim5,6, Fei Su4, Maria Gabriela Raso4, Yasmeen Rizvi2, Ming Zhao2, Huamin Wang4,5, Sunyoung S. Lee7, Timothy A. Yap2, Jordi Rodon2, Milind Javle7, and Funda Meric-Bernstam1,2,6  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Biliary tract cancers, which are rare and aggressive malignancies, are rich in clinically actionable molecular alterations. A major challenge in the field is the paucity of clinically relevant biliary tract cancer models that recapitulate the diverse molecular profiles of these tumors. The purpose of this study was to curate a collection of patient-derived xenograft (PDX) models that reflect the spectrum of genomic alterations present in biliary tract cancers to create a resource for modeling precision oncology.\u003Cbr>Experimental Design: PDXs were derived from biliary tract cancer samples collected from surgical resections or metastatic biopsies. Alterations present in the PDXs were identified by whole-exome sequencing and RNA sequencing. PDXs were treated with approved and investigational agents. Efficacy was assessed by change in tumor volume from baseline. Event-free survival was defined as the time to tumor doubling from baseline. Responses were categorized at day 21: >30% decrease in tumor\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | volume ¼ partial response, >20% increase in tumor volume ¼ progressive disease, and any non-partial response/progressive disease was considered stable disease.\u003Cbr>Results: Genomic sequencing demonstrated key actionable alterations across this cohort, including alterations in FGFR2, isocitrate dehydrogenase I, ERRB2, PIK3CA, PTEN, and KRAS. RNA sequencing demonstrated fusions and expression of antibody–drug conjugate targets, including TROP2, HER2, and Nectin4 . Therapeutic matching revealed objective responses to approved and investigational agents that have been shown to have antitumor activity clinically.\u003Cbr>Conclusions: In this study, we developed a catalog of biliary tract cancer PDXs that underwent comprehensive molecular profiling and therapeutic modeling. To date, this is one of the largest collections of biliary tract cancer PDX models and will facilitate the development of personalized treatments for patients with these aggressive malignancies. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nBiliary tract cancers, including intrahepatic cholangiocarcinoma (ICCA), extrahepatic CCA (ECCA), and gallbladder cancer, are  \n1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Hou","cbCairQIjFnhSGg1","https://ap.wps.com/l/cbCairQIjFnhSGg1","pdf",11176751,16,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"Why were patient-derived xenograft models needed for biliary tract cancers?\",\"answer\":\"Clinically relevant biliary tract cancer models are scarce and often fail to reflect the tumors’ diverse molecular profiles. PDX models were curated to represent this genomic spectrum for precision oncology research.\"},{\"question\":\"How were the PDX models developed and molecularly characterized?\",\"answer\":\"PDXs were derived from biliary tract cancer samples from surgical resections or metastatic biopsies. Whole-exome sequencing and RNA sequencing were used to identify alterations present in the models.\"},{\"question\":\"What kinds of molecular alterations and targets were identified?\",\"answer\":\"Genomic sequencing revealed actionable alterations including FGFR2, IDH1, ERBB2, PIK3CA, PTEN, and KRAS. RNA sequencing showed fusions and expression of antibody–drug conjugate targets including TROP2, HER2, and Nectin4.\"},{\"question\":\"How was treatment efficacy assessed and how were responses categorized?\",\"answer\":\"Efficacy was assessed by change in tumor volume from baseline, and event-free survival was defined as the time to tumor doubling. Responses at day 21 were categorized using tumor shrinkage and growth thresholds to distinguish objective responses from stable disease.\"}]","Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer | PDF",1790175292,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d54f475e0ebbbf723492dda572166406.webp",983,1315,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfd5126e41f3de4eab3186480a5a9bf1.webp",982,1314,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97ae14065aeea384dca9718f2980b7a1.webp",981,1312,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a38fdc454df022be652961e646cad710.webp",980,1311]